Growth Hormone Secretagogues

Growth hormone secretagogues are peptides (and one orally-active small molecule, MK-677) that stimulate pulsatile endogenous growth hormone release from the pituitary somatotrophs rather than supplying exogenous recombinant GH. The class falls into two mechanistic branches that are functionally complementary. The GHRH branch — sermorelin, CJC-1295 with and without DAC, and tesamorelin — consists of analogs of growth hormone-releasing hormone (the 44-residue hypothalamic factor isolated by Roger Guillemin's and Wylie Vale's groups in the early 1980s) that bind the GHRH receptor on pituitary somatotrophs. The ghrelin-receptor branch — GHRP-1, GHRP-2, GHRP-6, hexarelin, ipamorelin, and the orally-active MK-677 (ibutamoren) — consists of synthetic peptides and small molecules that bind the ghrelin receptor (GHSR1a, originally identified as the orphan growth hormone secretagogue receptor by Howard et al., Science 1996), which the endogenous gastric peptide ghrelin (Kojima et al., Nature 1999) is the natural ligand for. The two branches act through distinct receptors with different downstream signaling, and they are often co-administered to produce synergistic GH pulses — a stack-design pattern reflected in our /stacks/cjc-1295-ipamorelin and related entries.

Clinical translation in this family is uneven. Sermorelin (Geref, the 29-residue active fragment of GHRH) was FDA-approved for pediatric growth hormone deficiency in 1997 but withdrawn commercially in 2008 for non-safety reasons; it remains available through compounding pharmacy channels. Tesamorelin (Egrifta, a stabilized GHRH analog) is FDA-approved for HIV-associated lipodystrophy with visceral adipose tissue accumulation. CJC-1295 (with and without the drug affinity complex DAC) is investigational and used in research and consumer-research-channel contexts. Among the ghrelin-receptor agonists, MK-677 (ibutamoren) reached late-stage clinical trials for various indications without reaching approval and is now sold predominantly in research-channel and consumer-research-channel use. The GHRP series (GHRP-1, GHRP-2, GHRP-6) and hexarelin are research-channel only. The class as a whole sits firmly outside FDA-approved therapy for general GH supplementation, with appropriate clinical use restricted to validated medical indications (pediatric GHD, HIV lipodystrophy, adult-onset GHD with rigorous diagnosis).

This page is the family-level pillar covering the GH secretagogue class as a whole. For individual peptide pages with full evidence ratings, dosing, and references, follow the links to each member below.

Shared mechanism

The two mechanistic branches of the family act through distinct receptors with complementary downstream effects on pituitary GH release.

The GHRH branch (sermorelin, CJC-1295, CJC-1295 no-DAC, tesamorelin) acts at the GHRH receptor (GHRHR), a class B G-protein-coupled receptor expressed primarily on pituitary somatotrophs. GHRH receptor activation couples to Gs and elevates intracellular cAMP, driving GH synthesis and release from preformed secretory granules. The GHRH branch preserves the natural pulsatile GH release pattern (synchronized to GHRH and somatostatin oscillations) and produces a physiological GH pulse that respects the negative feedback from IGF-1 and somatostatin — limiting the maximum GH excursion and reducing the risk of pathological GH excess. The half-life of native GHRH is ~6-7 minutes; therapeutic analogs use various stabilization strategies (sermorelin: just the active 1-29 fragment, ~10 minute half-life; tesamorelin: trans-3-hexenoyl-Tyr1 modification; CJC-1295 no-DAC: Ala2 / Glu8 / Ala15 / Ala27 modifications, ~30 minute half-life; CJC-1295 with DAC: same modifications plus maleimido-propionic acid linker for irreversible albumin binding, ~6-8 day half-life).

The ghrelin-receptor branch (GHRP-1, GHRP-2, GHRP-6, hexarelin, ipamorelin, MK-677) acts at the ghrelin receptor (GHSR1a, the growth hormone secretagogue receptor), a class A G-protein-coupled receptor expressed on pituitary somatotrophs and on hypothalamic feeding circuits. GHSR1a activation couples primarily to Gq/11 with phospholipase-C-mediated calcium mobilization, driving GH release through a distinct intracellular signaling pathway from GHRH. The ghrelin-receptor branch produces both GH release and (through hypothalamic ghrelin-receptor effects) appetite stimulation and modest cortisol/prolactin elevations — the latter being more prominent for GHRP-2, GHRP-6, and hexarelin than for the more-selective ipamorelin. The endogenous ligand ghrelin has the unique octanoyl-Ser3 modification (catalyzed by ghrelin O-acyltransferase, GOAT) that confers receptor binding; the synthetic analogs do not require this modification because they bind through different structural features.

The co-administration logic for GHRH-branch + ghrelin-branch stacks (e.g. CJC-1295 + ipamorelin) reflects the receptor-pharmacology synergy: the two branches activate the same somatotrophs through distinct signaling pathways, producing GH release that exceeds either single agent at equivalent doses while preserving the pulsatile pattern that single-agent ghrelin-receptor agonism can erode through receptor desensitization. The synergy is well-documented in pituitary-cell culture and in vivo human GH-pulse studies.

History & discovery

The GH secretagogue story begins with two parallel discovery threads. The GHRH thread starts with Roger Guillemin's group at the Salk Institute and Wylie Vale's collaborative work in the early 1980s, who isolated GHRH from a human pancreatic tumor that produced ectopic GHRH causing acromegaly. The peptide was sequenced as a 44-residue C-terminally amidated peptide. The N-terminal 1-29 fragment retained essentially full activity, and synthetic GHRH(1-29) became sermorelin — the first clinically used GHRH analog. Sermorelin was FDA-approved as Geref in 1997 for pediatric growth hormone deficiency. The drug-affinity-complex strategy used in CJC-1295 (the [Asp3, Lys15, Ala29]-modified GHRH(1-29) with a maleimido-propionic acid linker for albumin attachment) was developed in the 2000s for half-life extension to ~8 days. Tesamorelin used different stabilizing modifications and was developed by Theratechnologies for HIV lipodystrophy, with FDA approval in 2010 (Falutz et al., AIDS 2008; J Acquir Immune Defic Syndr 2010).

The ghrelin-receptor thread starts with Cyril Bowers's observation in the early 1970s that Met-enkephalin and analogs unexpectedly stimulated GH release in pituitary cell cultures — an effect not explained by opioid pharmacology. Bowers and Frank Momany at USDA developed a series of synthetic peptides through systematic structural optimization of Met-enkephalin, producing GHRP-6 (the prototype, His-D-Trp-Ala-Trp-D-Phe-Lys-NH2, reported in the 1981 Momany Endocrinology paper) and the subsequent GHRP series (GHRP-1, GHRP-2). Hexarelin emerged later as a more potent congener. The molecular target of these peptides was unknown for years — they activated an orphan receptor that Howard, Feighner, and colleagues at Merck cloned in 1996 (Science) as the growth hormone secretagogue receptor (GHS-R, now GHSR1a). The endogenous ligand was identified three years later in 1999 by Kojima, Kangawa, Hosoda, and Matsuo at the National Cardiovascular Center in Osaka (Nature) as ghrelin — a 28-residue peptide produced by gastric X/A-like cells with a unique octanoyl modification on serine-3.

Merck developed the orally-active small-molecule ghrelin-receptor agonist MK-677 (ibutamoren) through 1990s small-molecule optimization following GHSR1a cloning. MK-677 reached late-stage clinical trials for various indications including osteoporosis (Murphy et al., JCEM 2001), sarcopenia in older adults, and obesity-related metabolic effects, but did not reach FDA approval for any indication. Svensson et al. (J Bone Miner Res 1998) had reported earlier on MK-677 effects in obese young males. Ipamorelin emerged as a selective ghrelin-receptor agonist (Helsinn Therapeutics) with reduced cortisol and prolactin elevations compared with the broader GHRP class — the property that made it the preferred ghrelin-receptor-branch peptide for many research and consumer-research-channel users (Venkova et al., J Pharmacol Exp Ther 2009 demonstrated efficacy in postoperative ileus).

The modern era of the class is characterized by mostly stalled clinical translation alongside continued research-channel and consumer-research-channel use. Recombinant human GH (somatropin) remains the validated therapy for clinically defined growth hormone deficiency, and the GLP-1 / incretin class has displaced GH-secretagogue interest in metabolic and body-composition indications. Within the family, the most-used contemporary agents are tesamorelin (the only one with current branded availability), MK-677 (research-channel oral), and ipamorelin / CJC-1295 stacks (research-channel injectable). The dominant search interest in the class is from the fitness and longevity communities, where the framing emphasizes endogenous GH pulse stimulation as a 'gentler' alternative to recombinant GH supplementation — a framing that has clinical-evidence support for specific medical indications but not for general fitness or anti-aging use.

State of evidence

Evidence in this class is concentrated in two FDA-approved indications and otherwise distributed across research-tier studies. Tesamorelin has Phase 3 RCT support for HIV-associated lipodystrophy with visceral adipose accumulation (Falutz 2008 AIDS, 2010 JAIDS) and remains commercially available as Egrifta. Sermorelin had FDA approval for pediatric growth hormone deficiency from 1997 to 2008 (commercial withdrawal was for non-safety reasons; the molecule remains available through compounding) and is supported by sufficient pediatric efficacy data. CJC-1295 has investigational data on GH/IGF-1 elevation but no approved indication. MK-677 (ibutamoren) has been studied in osteoporosis (Murphy 2001 JCEM), obesity-related metabolic effects (Svensson 1998 J Bone Miner Res), sarcopenia, and other settings without producing an FDA-approval pathway. Ipamorelin has preclinical and limited clinical data including postoperative ileus (Venkova 2009 J Pharmacol Exp Ther). The GHRP series has limited modern clinical data and is dominated by research-channel use.

For patients, the validated medical indications are narrow: clinically defined pediatric growth hormone deficiency (where recombinant GH/somatropin is the standard, sermorelin is an alternative), adult-onset growth hormone deficiency from hypothalamic-pituitary disease (where GH replacement is appropriate after rigorous endocrinology workup), and HIV-associated lipodystrophy (tesamorelin). The class is not appropriate for general fitness, anti-aging, or body-composition use without clinically validated GHD diagnosis. Concerns with chronic GH-secretagogue use include insulin resistance, fluid retention, carpal tunnel syndrome, and (with the ghrelin-receptor branch) appetite stimulation that can produce unintended weight gain. Recombinant GH itself carries a class boxed warning relevant to peripheral malignancy risk in adults — relevant by extension to the GH-secretagogue class to the extent that downstream GH/IGF-1 elevation is the operative pharmacology.

How members compare

Within the class, the principal comparison is GHRH branch vs ghrelin-receptor branch. GHRH-branch agents (sermorelin, tesamorelin, CJC-1295) preserve pulsatile physiology with built-in negative feedback, no significant cortisol/prolactin elevation, no appetite effect, and produce modest GH/IGF-1 increases. Ghrelin-receptor agents (GHRP-2, GHRP-6, hexarelin, ipamorelin, MK-677) produce additional appetite stimulation (which can be unwanted), variable cortisol/prolactin elevations (most pronounced with the older GHRPs, minimal with ipamorelin and MK-677), and (with chronic dosing) potential receptor desensitization. Stacking the two branches produces synergy that exceeds either alone. MK-677 is unique in being orally active.

Outside the GH-secretagogue family, the principal comparator is recombinant human growth hormone (somatropin) — supplied as exogenous GH itself rather than stimulating endogenous release. Somatropin has the largest evidence base, the broadest set of approved indications (pediatric GHD, adult-onset GHD, Turner syndrome, Prader-Willi syndrome, idiopathic short stature, AIDS wasting), and the strongest off-label fitness and anti-aging community use. The GH-secretagogue class is positioned as an alternative for patients who want endogenous-pulse stimulation rather than continuous-release exogenous GH, and for indications (HIV lipodystrophy via tesamorelin) where the GHRH-receptor pathway is the validated mechanism. For body-composition and weight-management indications outside HIV lipodystrophy, the GLP-1 / incretin class has substantially displaced GH-secretagogue interest in mainstream clinical practice.

Frequently asked questions

References

• Design, synthesis, and biological activity of peptides which release growth hormone in vitroOriginal Research

  Momany FA, Bowers CY, Reynolds GA, Hong A, and Newlander K, Endocrinology 1981. The foundational paper of the GHRP series, reporting the design and biological activity of the synthetic peptides developed at Tulane (Bowers) and USDA (Momany) through systematic structural optimization of Met-enkephalin. Establishes the GHRP class.

• A receptor in pituitary and hypothalamus that functions in growth hormone releaseOriginal Research

  Howard AD, Feighner SD, Cully DF, and colleagues at Merck Research Laboratories, Science 1996. Cloned the orphan growth hormone secretagogue receptor (GHS-R, now GHSR1a) — identified through its responsiveness to the synthetic GHRP class. Three years before ghrelin's discovery as the endogenous ligand. The foundational receptor paper for the ghrelin-branch GH secretagogues.

• Ghrelin is a growth-hormone-releasing acylated peptide from stomachOriginal Research

  Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, and Kangawa K, Nature 1999. The discovery of ghrelin as the endogenous ligand of the GHSR1a receptor — a 28-residue peptide produced by gastric X/A-like cells with a unique octanoyl modification on serine-3. One of the most consequential gut-hormone discoveries of the past 30 years.

• Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulationClinical Trial

  Falutz J and colleagues, AIDS 2008. The pivotal long-term safety trial of tesamorelin in HIV patients with visceral adipose accumulation, demonstrating sustained reduction in visceral fat with acceptable safety. Foundational evidence for the FDA approval of tesamorelin (Egrifta) in 2010 for HIV-associated lipodystrophy.

• Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extensionClinical Trial

  Falutz J and colleagues, Journal of Acquired Immune Deficiency Syndromes 2010. The Phase 3 RCT and safety extension supporting tesamorelin's FDA approval. Established the dosing, efficacy, and safety profile that defines current tesamorelin use in HIV lipodystrophy.

• Effect of alendronate and MK-677 (a growth hormone secretagogue), individually and in combination, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic womenClinical Trial

  Murphy MG and colleagues, Journal of Clinical Endocrinology and Metabolism 2001. Important MK-677 (ibutamoren) clinical trial in postmenopausal osteoporotic women, characterizing the effects on bone turnover markers and BMD. Part of the MK-677 development program that did not reach FDA approval but generated substantial clinical-trial evidence.

• Treatment with the oral growth hormone secretagogue MK-677 increases markers of bone formation and bone resorption in obese young malesClinical Trial

  Svensson J and colleagues, Journal of Bone and Mineral Research 1998. Earlier MK-677 trial in obese young males characterizing bone metabolism effects. Together with Murphy 2001, defines the MK-677 bone-effects literature.

• Efficacy of ipamorelin, a novel ghrelin mimetic, in a rodent model of postoperative ileusOriginal Research

Related goals